Pediatrix Medical Group Hits New 52-Week High of $21.24

Pediatrix Medical Group, Inc. has reached a significant milestone by hitting a new 52-week high of USD 21.24 on November 3, 2025. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated remarkable growth over the past year.
With a market capitalization of USD 1,476 million, Pediatrix Medical Group has shown a staggering 205.07% increase in its stock price compared to the S&P 500's performance of 19.89%. The company's price-to-earnings (P/E) ratio stands at 8.00, indicating a favorable valuation relative to its earnings. Additionally, the stock's price-to-book ratio is 1.77, further reflecting its market position.

Pediatrix Medical Group's financial health is highlighted by a return on equity of 18.01% and a debt-to-equity ratio of 0.33, suggesting a solid balance sheet. The company has also reported impressive operating cash flow, reaching USD 244.56 million, and a high interest coverage ratio of 755.9. With institutional holdings at 100%, the company is well-positioned within the market, showcasing its robust fundamentals and operational efficiency.